TY - JOUR
T1 - Prevention, Diagnosis, and Treatment of VTE in Patients With Coronavirus Disease 2019
T2 - CHEST Guideline and Expert Panel Report
AU - Moores, Lisa K.
AU - Tritschler, Tobias
AU - Brosnahan, Shari
AU - Carrier, Marc
AU - Collen, Jacob F.
AU - Doerschug, Kevin
AU - Holley, Aaron B.
AU - Jimenez, David
AU - Le Gal, Gregoire
AU - Rali, Parth
AU - Wells, Philip
N1 - Publisher Copyright:
© 2020
PY - 2020/9
Y1 - 2020/9
N2 - Background: Emerging evidence shows that severe coronavirus disease 2019 (COVID-19) can be complicated by a significant coagulopathy, that likely manifests in the form of both microthrombosis and VTE. This recognition has led to the urgent need for practical guidance regarding prevention, diagnosis, and treatment of VTE. Methods: A group of approved panelists developed key clinical questions by using the PICO (Population, Intervention, Comparator, Outcome) format that addressed urgent clinical questions regarding the prevention, diagnosis, and treatment of VTE in patients with COVID-19. MEDLINE (via PubMed or Ovid), Embase, and Cochrane Controlled Register of Trials were systematically searched for relevant literature, and references were screened for inclusion. Validated evaluation tools were used to grade the level of evidence to support each recommendation. When evidence did not exist, guidance was developed based on consensus using the modified Delphi process. Results: The systematic review and critical analysis of the literature based on 13 Population, Intervention, Comparator, Outcome questions resulted in 22 statements. Very little evidence exists in the COVID-19 population. The panel thus used expert consensus and existing evidence-based guidelines to craft the guidance statements. Conclusions: The evidence on the optimal strategies to prevent, diagnose, and treat VTE in patients with COVID-19 is sparse but rapidly evolving.
AB - Background: Emerging evidence shows that severe coronavirus disease 2019 (COVID-19) can be complicated by a significant coagulopathy, that likely manifests in the form of both microthrombosis and VTE. This recognition has led to the urgent need for practical guidance regarding prevention, diagnosis, and treatment of VTE. Methods: A group of approved panelists developed key clinical questions by using the PICO (Population, Intervention, Comparator, Outcome) format that addressed urgent clinical questions regarding the prevention, diagnosis, and treatment of VTE in patients with COVID-19. MEDLINE (via PubMed or Ovid), Embase, and Cochrane Controlled Register of Trials were systematically searched for relevant literature, and references were screened for inclusion. Validated evaluation tools were used to grade the level of evidence to support each recommendation. When evidence did not exist, guidance was developed based on consensus using the modified Delphi process. Results: The systematic review and critical analysis of the literature based on 13 Population, Intervention, Comparator, Outcome questions resulted in 22 statements. Very little evidence exists in the COVID-19 population. The panel thus used expert consensus and existing evidence-based guidelines to craft the guidance statements. Conclusions: The evidence on the optimal strategies to prevent, diagnose, and treat VTE in patients with COVID-19 is sparse but rapidly evolving.
KW - COVID-19
KW - DIC
KW - DVT
KW - VTE
KW - hypercoagulability
KW - pulmonary embolism
UR - http://www.scopus.com/inward/record.url?scp=85089564112&partnerID=8YFLogxK
U2 - 10.1016/j.chest.2020.05.559
DO - 10.1016/j.chest.2020.05.559
M3 - Article
C2 - 32502594
AN - SCOPUS:85089564112
SN - 0012-3692
VL - 158
SP - 1143
EP - 1163
JO - Chest
JF - Chest
IS - 3
ER -